ID
BMRN icon

Integral Derivatives’s BioMarin Pharmaceuticals BMRN Stock Holding History

Integral Derivatives’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,260
Closed -$342K – 870
2015
Q4 		$342K Buy
+3,260
New +$340K 0.01% 766
2015
Q3 		– Sell
-2,660
Closed -$364K – 1098
2015
Q2 		$364K Buy
+2,660
New +$330K 0.01% 808
2014
Q1 		– Sell
-9,338
Closed -$656K – 1314
2013
Q4 		$656K Buy
+9,338
New +$634K 0.01% 949

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Integral Derivatives's BMRN Position: Q1 2016 in Review

Integral Derivatives sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2016, closing a stake of 3,260 shares — an estimated $342K sold.

Integral Derivatives first reported a position in BMRN in Q4 2013 and held it in 3 quarters. The position peaked at $656K in Q4 2013. 391 funds tracked by Wall St. Rank hold BMRN as of Q1 2016.

  • Integral Derivatives reported no remaining BioMarin Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Integral Derivatives sold 3,260 BioMarin Pharmaceuticals shares in Q1 2016, an estimated $342K.
  • Integral Derivatives first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • Integral Derivatives's BioMarin Pharmaceuticals position peaked at $656K in Q4 2013.
  • 391 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2016.

Based on Integral Derivatives's 13F filing for Q1 2016, filed 12 Apr 2016.